From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the thyroid carcinoma pharmaceutical market based on detailed primary and secondary market research. Content includes a summary of disease etiology, pathophysiology, and drug targets; epidemiological projections, including estimates of drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including regulatory approval timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast of key branded agents with supporting tables, figures, and methods.

Questions Answered:

  • The overall thyroid carcinoma population will increase due to improved diagnostic procedures. How large is the drug-treatable thyroid carcinoma population, and how will drug-treatment rates change over time? What are the drivers and constraints in the thyroid carcinoma market?
  • While surgery is the mainstay of treatment, four therapies have been approved since 2011 for the treatment of advanced cases of thyroid carcinoma. What is the current state of treatment in thyroid carcinoma? What are the most commonly prescribed drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • There is only one drug class in late-phase clinical development for thyroid carcinoma, but  there are different drug classes in early-phase development, such as the immunotherapies. What pipeline products are most promising, and what sales/uptake could they secure in thyroid carcinoma? What therapies of note are progressing in earlier phases?
  • We have identified several unmet needs and challenges in the thyroid carcinoma landscape. What are the key unmet needs in the treatment of thyroid carcinoma according to interviewed thought leaders? Is it likely that these unmet needs will be addressed or partially addressed during our forecast period?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with thought leaders.

Epidemiology: Diagnosed incident cases of thyroid carcinoma (WHO ICD-10 coding system and ICD-O3 histological classification of tumors) by disease stage (stage I, stage II, stage III, stage IVa, stage IVb, stage IVc) and thyroid carcinoma histologies (follicular, papillary, medullary, and anaplastic). Recurrent incident (distant metastatic) cases of thyroid carcinoma.

Population segments in market forecast: Locally advanced radioactive iodine-avid differentiated thyroid carcinoma; locally advanced and metastatic radioactive iodine-refractory differentiated thyroid carcinoma; locally advanced and metastatic symptomatic and/or progressive medullary thyroid carcinoma.

Emerging therapies: Phase III: 1 drug; Phase II: 9 drugs; coverage of selected Phase I products.

Table of contents

  • Thyroid Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
        • Thyroid Carcinoma Market Parameters and Forecast
        • Thyroid Carcinoma SWOT Analysis
    • Commercial Outlook
      • Market Outlook
        • Key Findings
        • Market Overview
        • Thyroid Carcinoma Market Landscape
      • Drivers and Constraints
        • What Factors Are Driving the Market for Thyroid Carcinoma?
        • What Factors Are Constraining the Market for Thyroid Carcinoma?
        • Estimated Sales of Key Branded Agents in the Major Markets
      • Segment-Specific Trends
        • Radioactive Iodine-Avid Differentiated Thyroid Carcinoma
        • Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma
        • Symptomatic and/or Progressive Medullary Thyroid Carcinoma
    • Forecast
      • Forecast Sales of Key Therapies in Thyroid Carcinoma
    • Etiology and Pathophysiology
      • Etiology
        • Molecular Aberrations in Thyroid Carcinoma
        • Environmental Risk Factors for Developing Thyroid Cancer
        • Inherited Risk Factors for Developing Thyroid Carcinoma
      • Disease Pathophysiology
        • Staging and Classification
          • Tumor, Node, Metastasis Status Staging System for Thyroid Cancer
          • Stage Grouping System for Thyroid Carcinoma
        • Key Pathways and Drug Targets
          • Molecular Targets of Signaling Pathways in Thyroid Carcinoma
      • Epidemiology Overview
        • Introduction
          • Key Findings
          • Diagnosed Incidence of Thyroid Carcinoma Across the Mature Markets, 2015 and 2025
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Thyroid Carcinoma Over the Next Ten Years
          • Number of Additional Incident Cases of Thyroid Carcinoma Incurred Over the Period 2015-2025 Across the Countries Under Study
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Incidence of Thyroid Carcinoma
          • Diagnosed Incident Cases of Thyroid Carcinoma
          • Disease Definition
          • Methods
          • Sources Used for Stage Distribution of Thyroid Carcinoma
          • Diagnosed Incident Cases of Follicular Thyroid Carcinoma by Stage Distribution
          • Diagnosed Incident Cases of Medullary Thyroid Carcinoma by Stage Distribution
          • Diagnosed Incident Cases of Papillary Thyroid Carcinoma by Stage Distribution
          • Diagnosed Incident Cases of Anaplastic Thyroid Carcinoma by Stage Distribution
          • Definition
          • Methods
          • Sources Used for Recurrent Incidence of Thyroid Carcinoma
          • Recurrent Incident Cases of Thyroid Carcinoma
          • Differentiated Thyroid Carcinoma Patient Flow
          • Medullary Thyroid Carcinoma Patient Flow
          • Anaplastic Thyroid Carcinoma Patient Flow
          • Sources Used for Drug-Treatable Populations of Thyroid Carcinoma
          • Drug-Treatable Cases of Thyroid Carcinoma
          • Drug-Treated Cases of Thyroid Carcinoma
      • Current Treatment Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Treatment Overview
        • Diagnosis
          • Diagnostic Tests and Criteria
          • Treatment Providers and Referral Patterns
          • Expert Insight on Diagnosis of Thyroid Carcinoma
        • Treatment Goals
          • Key End Points Used in Clinical Trials for Thyroid Carcinoma
          • Key Expert Insights on Clinical End Points
        • Key Current Therapies
          • Overview
          • Mechanism of Action of Key Current Drugs for Thyroid Carcinoma
          • Current Treatments Used for Thyroid Carcinoma
          • Market Events Impacting the Use of Key Current Therapies in Thyroid Carcinoma
          • Clinical Trial Outcomes for Caprelsa
          • Clinical Analysis of Caprelsa for the Treatment of Medullary Thyroid Cancer
          • Advantages and Disadvantages of Caprelsa
          • Ongoing Clinical Development
          • Expert Insight on Caprelsa
          • Clinical Trial Outcomes for Cometriq
          • Clinical Analysis of Cometriq for the Treatment of Medullary Thyroid Carcinoma
          • Advantages and Disadvantages of Cometriq
          • Ongoing Clinical Development
          • Expert Insight on Cometriq
          • Clinical Trial Outcomes for Nexavar
          • Clinical Analysis of Nexavar for the Treatment of Differentiated Thyroid Carcinoma
          • Advantages and Disadvantages of Nexavar
          • Ongoing Clinical Development
          • Expert Insight on Nexavar
          • Clinical Trial Outcomes for Lenvima
          • Clinical Analysis of Lenvima for the Treatment of Differentiated Thyroid Carcinoma
          • Advantages and Disadvantages of Lenvima
          • Ongoing Clinical Development
          • Expert Insight on Lenvima
        • Medical Practice
          • Differentiated Thyroid Carcinoma
          • Medullary Thyroid Carcinoma
          • Anaplastic Thyroid Carcinoma
          • Thyroid Carcinoma Treatment Guidelines, by Market
          • United States
          • Europe
          • Generalized Treatment Decision Tree for Differentiated Thyroid Carcinoma
          • Generalized Treatment Decision Tree for Medullary Thyroid Carcinoma
          • Generalized Treatment Decision Tree for Anaplastic Thyroid Carcinoma
      • Unmet Need Overview
        • Introduction
          • Key Findings
          • Expert Insight
        • Attainment of Unmet Needs
          • Current Attainment of Unmet Needs in Thyroid Carcinoma
          • Future Attainment of Unmet Needs in Thyroid Carcinoma
          • Top Unmet Needs in Thyroid Carcinoma—Current and Future Attainment
      • Emerging Therapies Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Pipeline Overview
          • Pipeline Trends for Thyroid Carcinoma
        • Late-Phase Pipeline Analysis
          • Notable Developments in the Late-Phase Pipeline for Thyroid Carcinoma
          • Therapies in Late-Phase Development for Thyroid Carcinoma
          • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Thyroid Carcinoma
        • Orphan Drug Designation
          • Expanded Market Exclusivity
          • Tax Credits
          • Support During the Drug Approval Process
          • Grants
          • Market Exclusivity
          • Fee Reductions
        • Patient Registries
          • Patient Registries for Thyroid Carcinoma
        • Key Emerging Therapies
          • Clinical Data on Selumetinib for the Treatment of Thyroid Carcinoma
          • Selumetinib Clinical Development
          • Ongoing Clinical Development of Selumetinib for the Treatment of Thyroid Carcinoma
          • Expert Insight
          • Expert Insight on Selumetinib
          • Expectations for Launch and Sales Opportunity of Selumetinib in Differentiated Thyroid Carcinoma
        • Early-Phase Pipeline Analysis
          • Notable Developments in the Early-Phase Pipeline for Thyroid Carcinoma
          • Select Early-Phase Compounds in Development for Thyroid Carcinoma
          • Keytruda and Clinical Development
          • Sapanisertib and Clinical Development
      • Access and Reimbursement Overview
        • Region-Specific Reimbursement Practices
          • Reimbursement Environment for Thyroid Carcinoma Therapies in the United States
          • Reimbursement Environment for Thyroid Carcinoma Therapies in the EU5
      • Methodology
        • Appendix
          • Key Abbreviations Related to Thyroid Carcinoma
          • Brands, Marketers, and Generic Availability of Key Therapies for Thyroid Carcinoma, by Market
          • Experts Interviewed
          • Thyroid Carcinoma Bibliography

      Author(s): Laura Vinuesa, DVM, MSc

      Laura Vinuesa, DVM, M.Sc., is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy.

      Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a M.Sc. in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies.

      lvinuesa@TeamDRG.com